Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis
about
Production of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vectorVaccines in development against West Nile virusPreparation and immunogenic properties of a recombinant West Nile subunit vaccineAntibody Recognition of Cell Surface-Associated NS1 Triggers Fc- Receptor-Mediated Phagocytosis and Clearance of West Nile Virus-Infected CellsComplex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses.A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cellsImmunogenicity and Protective Efficacy of a Recombinant Subunit West Nile Virus Vaccine in Rhesus MonkeysEvaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamstersA recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virusImmunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal deliveryEvaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection.Current trends in West Nile virus vaccine development.A recombinant novirhabdovirus presenting at the surface the E Glycoprotein from West Nile Virus (WNV) is immunogenic and provides partial protection against lethal WNV challenge in BALB/c mice.Protective immunity to Japanese encephalitis virus associated with anti-NS1 antibodies in a mouse model.Tick-borne Encephalitis Vaccines.A review of vaccine approaches for West Nile virus.Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus.Technologies for the development of West Nile virus vaccines.An Overview of Current Approaches Toward the Treatment and Prevention of West Nile Virus Infection.
P2860
Q26247032-22F2D509-916E-4BC3-B167-4C88A8CF48A0Q26999702-999AA2E1-F5A9-479D-BDE7-C2B4D4960103Q27478202-20848AB2-5AC5-4284-B4FC-CB8230302E23Q27481025-AF1C4299-456A-448B-9C38-7FADB5B30F8BQ27481420-032CE269-36B6-4AC3-A108-968F36B9D6C4Q27487992-C86023DF-F090-4665-8263-41420F1A3CC6Q27489620-03C458B0-8735-44FA-94FA-493297F9F30EQ27490208-0C4EBFB1-21BB-4CFA-9FEB-BAD664985313Q28740740-32CBC5F7-B210-47BB-A7EF-F0371EDADF55Q33584872-3D1D2400-9F71-470B-8A15-F3AA930F5084Q33880730-ED077BF1-8623-47BD-B130-F435A4C3236FQ34788758-A191B7B2-EC64-405D-8461-E3EE110FC240Q35129151-8415E787-66F2-46BF-B18A-20A175FECC33Q36156558-AE9F4B84-2491-46EE-A807-E21C94D25BECQ37127083-978265E9-27EB-4FC7-AD42-66E05D5CAA6BQ37236968-B14B43D8-A605-4EEA-A94E-36DE72D568F9Q37842337-6F8105B6-AF8D-4773-9990-3FEA7767FC88Q38269151-994F6AF3-536C-4934-8921-D27CE210AED0Q38866173-D5191F72-DEB0-43A1-91C6-11C6652A48F4
P2860
Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Efficacy and durability of a r ...... rs from West Nile encephalitis
@ast
Efficacy and durability of a r ...... rs from West Nile encephalitis
@en
Efficacy and durability of a r ...... rs from West Nile encephalitis
@nl
type
label
Efficacy and durability of a r ...... rs from West Nile encephalitis
@ast
Efficacy and durability of a r ...... rs from West Nile encephalitis
@en
Efficacy and durability of a r ...... rs from West Nile encephalitis
@nl
prefLabel
Efficacy and durability of a r ...... rs from West Nile encephalitis
@ast
Efficacy and durability of a r ...... rs from West Nile encephalitis
@en
Efficacy and durability of a r ...... rs from West Nile encephalitis
@nl
P2093
P2860
P50
P1433
P1476
Efficacy and durability of a r ...... rs from West Nile encephalitis
@en
P2093
Beth-Ann Coller
Carolyn Weeks-Levy
David E Clements
Douglas M Watts
Michael M Lieberman
Patrick C Newman
Steven Ogata
P2860
P304
P356
10.1016/J.VACCINE.2006.08.008
P407
P577
2007-04-12T00:00:00Z